WHO ICTRP trial

PROgnostic value of precision medicine in patients with Myocardial Infarction…

EUCTR2020-006009-43-IT · EU Clinical Trials Register · Authorised

Key facts

Trial ID EUCTR2020-006009-43-IT
Public title PROgnostic value of precision medicine in patients with Myocardial Infarction and non-obStructive coronary artEries: the PROMISE study.
Scientific title PROgnostic value of precision medicine in patients with Myocardial Infarction and non-obStructive coronary artEries: the PROMISE study. - PROMISE
Primary sponsor FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
Registry EU Clinical Trials Register
Recruitment status Authorised
Study type Interventional clinical trial of medicinal product
Phase Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes
Countries Italy
Conditions Patients with Myocardial Infarction and non-obStructive coronary artEries MedDRA version: 20.0 Level: HLT Classification code 10011085 Term: Ischaemic coronary artery disorders System Organ Class: 100000004849 ;Therapeutic area: Diseases…
Interventions Product Name: TORVAST Product Code: [TORVAST] Pharmaceutical Form: Tablet INN or Proposed INN: ATORVASTATINA CAS Number: 134523-00-5 Current Sponsor code: ATORVASTATINA Concentration unit: mg milligram(s) Concentration type: up to…
Registration date Apr 6, 2021
Target size 180
Secondary IDs PROMISE
Registry page clinicaltrialsregister.eu

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations